Urothelial carcinoma (UC) is a highly aggressive malignancy with high incidence and severe complications, significantly impacting patients’ quality of life and survival outcomes. In recent years, there have been remarkable advances in both the diagnosis and treatment of UC. At the 2025 Pujiang Uro-Oncology Conference—jointly organized by the CSCO Urothelial Carcinoma Expert Committee, CSCO Renal Cancer Expert Committee, the Chinese Urologic Oncology Cooperative Group, the Beijing Health Promotion Association Chen Jumei Public Welfare Foundation, and the Shanghai Urologic Oncology Institute, and co-organized by Fudan University Cancer Hospital—Professor Jinchun Xing of the First Affiliated Hospital of Xiamen University delivered an insightful lecture on the latest breakthroughs and future directions in UC management.

At the recently concluded 2025 Pujiang Uro-Oncology Conference, the “High-Quality Development Forum on Urologic Oncology” drew considerable attention as leading domestic and international experts shared cutting-edge clinical and translational research progress. Professor Zhuowei Liu from Sun Yat-sen University Cancer Center (SYSUCC) was invited to present his team’s series of innovative studies in the field of urothelial carcinoma (UC). His talk systematically showcased how investigator-initiated trials (IITs)—ranging from refinements in radical surgery to mechanistic studies of therapeutic resistance—are driving meaningful change in clinical practice and advancing the field.

In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang Uro-Oncology Conference, Professor Qing Zou of Jiangsu Cancer Hospital shared the latest developments in the diagnosis and treatment of representative urologic tumors such as kidney cancer and non–muscle-invasive bladder cancer (NMIBC). He also discussed the implementation of innovative technologies, MDT collaboration, and the experience of building a full-course management system.